2026-05-17T01:16:09Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/193132024-09-27T09:42:36Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Tundidor, Isabel author Seijo-Vila, Marta author Blasco-Benito, Sandra author Rubert-Hernández, María author Adámez, Sandra author Andradas, Clara author Manzano, Sara author Álvarez-López, Isabel author Sarasqueta, Cristina author Villa-Morales, María author González-Lois, Carmen author Ramírez-Medina, Esther author Almoguera, Belén author Sánchez-López, Antonio J author Bindila, Laura author Hamann, Sigrid author Arnold, Norbert author Röcken, Christoph author Heras-Murillo, Ignacio author Sancho, David author Moreno-Bueno, Gema author Caffarel, María M author Guzmán, Manuel author Sánchez, Cristina author Pérez-Gómez, Eduardo author 2023-05-30 Clinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents >70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late as 15 years after treatment discontinuation. Seeking therapeutic approaches as well as screening tools to properly identify those patients with a higher risk of recurrence is therefore essential. Here, we report that the lipid-degrading enzyme fatty acid amide hydrolase (FAAH) is a predictor of long-term survival in patients with luminal BC, and that it blocks tumor progression and lung metastasis in cell and mouse models of BC. Together, our findings highlight the potential of FAAH as a biomarker with prognostic value in luminal BC and as a therapeutic target in metastatic disease. Nat Commun. 2023 May 30;14(1):3130. 10.1038/s41467-023-38750-9 2041-1723 Nature communications 37253733 http://hdl.handle.net/20.500.12105/19313 Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer.